An Open-Label, Multicenter Phase I Dose Escalation Study To Characterize Safety, Tolerability, Preliminary Antitumor Activity, Pharmacokinetics And Maximum Tolerated Dose Of VIP152 (BAY 1251152) In Subjects With Advanced Cancer Read more
An expanded access protocol for mobocertinib in refractory Non-Small Cell Lung Cancer patients with EGFR exon20 insertion mutations Read more
A Randomized, Open-label Phase 2 Clinical Trial of BMS-986012 in Combination with Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer Read more
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study Of Pembrolizumab (MK-3475) In Combination With Concurrent Chemoradiation Therapy Followed By Pembrolizumab With Or Without Olaparib (MK-7339), Compared To Concurrent Chemoradiation Therapy Alone In Participants With Actively Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) Read more
A Phase 2 Trial of MRTX849 in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation Read more
A Phase 1b/2 Clinical Study Of Intratumoral Administration Of V937 In Combination With Pembrolizumab (MK-3475) In Participants With Advanced/Metastatic Solid Tumors Read more
A Phase 1/2, Open-Label, Dose-Escalation, Safety And Tolerability Study Of NC318 In Subjects With Advanced Or Metastatic Solid Tumors Read more
A Phase 1/2, Open-Label, Dose-Escalation, Safety And Tolerability Study Of NC410 In Subjects With Advanced Or Metastatic Solid Tumors Read more
A Phase 1, Open-Label, Multi-Center, Dose-Finding, Pharmacokinetic, Safety And Tolerability Study Of Pf-07265807 In Participants With Selected Advanced Or Metastatic Solid Tumor Malignancies Read more
